A venture capital firm with offices throughout China manages about USD 1 billion in committed capital with three USD funds and three RMB funds. The firm typically invests in series A and B rounds. The firm can invest anywhere from a few hundred thousand dollars up to ten million or more over a 10 year horizon. At present, the firm is looking for new investment opportunities in Greater China, while it also considers US- or EU-based companies that are Chinese-led or have a China angle.

The firm seeks to invest in a broad array of technologies including therapeutics, medical devices, IVD, healthcare big data and mHealth. Within therapeutics, the firm is interested in reformulated and generic drugs. The firm typically does not consider novel drugs. Within medical devices, the firm is interested in disposable devices and products that address large unmet medical need in China. The firm is opportunistic in terms of subsectors and stage of development. Historically, the firm invested in radiology imaging, clinical cell and molecular genetics testing, POC devices, mobile health, diagnostics and genomics, and drug discovery.

The firm is looking for competent and experienced management teams. The firm typically seeks a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Germany-based corporate VC with offices worldwide invests in medical technology companies that are strategically relevant to its parent firm. Investments in equity rounds range from $1-5 million, and are made worldwide.

The fund’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the fund focuses on products used in a hospital setting. The fund also invests in healthcare IT solutions that add value to imaging and diagnostics, such as data-as-a-service products. The fund is potentially interested in medical robotics. The fund will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The fund generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A publicly-traded investment fund founded in 2001 and based in Switzerland invests in life science companies at both the developmental stage and also the growth/expansion stage, and usually makes 5-6 venture investments per year with half of their capital being deployed in the U.S. Only pre-clinical opportunities that are close to entering the clinic will be considered, however an exception may be made for novel/breakthrough science that has the possibility for a large syndicate. The firm’s early-stage investments are typically $5M-1$0M, and later-stage investments range from $10M-$25M. The firm invests primarily in Europe and the USA, but has also invested in Canada and is open to opportunities in the Middle East.

The firm invests primarily in therapeutics and is also interested in diagnostics, devices, and technologies with the potential to lead to therapeutic development (eg. drug discovery platforms). In the therapeutics field, the firm generally invests in clinical-stage opportunities. The firm invests in therapeutic areas where a result can be achieved with a reasonable amount of money, and therefore does not invest in highly capital-intensive therapeutic markets such as cardiovascular diseases, or large markets in metabolic disease such as diabetes or high cholesterol (smaller markets within metabolic disease may be of interest). Similarly, the fund typically avoids fields that are less well understood, such as CNS disorders or psychiatry. The firm is open to investing in orphan diseases.

In the devices and diagnostics field, the firm is open to investing in both companies with products under development and also companies with approved products that require commercialization-stage capital. For diagnostics, the firm focuses on innovative diagnostic technologies including biomarkers. As for medical devices, the firm focuses on devices that have a therapeutic application, including delivery devices, cardiac devices, and catheters; the firm prefers to invest in devices that require regulatory approval (Class 2 and 3 devices), rather than less regulated or disposable medical devices.

The firm invests in both private and public companies. Only U.S. companies with a headquarters on the West or East coast are considered. The fund has no fixed requirements for entrepreneurs but prefers to work with experienced management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A strategic consulting firm has a venture capital arm with offices in the US Midwest and Shanghai, China. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the China market by providing resources in the network. The firm is currently raising a fund predicted to close mid-year 2016. The firm is seeking five new investments within the next year, and typically makes $1M to several million dollar investments per company in Series A, B, and C rounds. The firm focuses on US-based companies, though is open to companies on a global-level.

The firm is indication agnostic and open to technology in all sectors of life science – medical devices, therapeutics, diagnostics, and healthcare IT. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably in Series B. The firm will also look at on-the-market products as well as lab equipment and drug development enabling technology.

The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and private equity firm with offices in Israel and Massachusetts has historically invested in in very early stage companies in therapeutics and diagnostics, but now is moving to mid-stage to later stage companies, primarily in medical devices. While the firm has made several lead investments, the firm typically co-invests, seeking partners with large USA private equity funds to make co-investments at $20 million and upwards. The firm currently manages a $120 million fund, and looks to make 2-3 investments within the next year. The firm is open to companies based in the USA, Europe, Israel, and Canada.

While having made investments in therapeutics and diagnostics in the past, the firm now focuses on innovative medical devices. The firm is open to 510K and PMA devices, as well as all indications. The firm prefers to see later stage post-product technology with proven clinical data, and may be interested in companies in clinical stages close to commercialization. The firm is also open to lab equipment and drug development enabling technology.

The firm requires companies to have an established management team, though will also help fill the team, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based on the US East Coast has a venture fund that makes direct venture investments in healthcare and technology startups. The fund was established by successful entrepreneurs and investors to meet the need for seed and early stage funding for life science and healthcare companies. The fund has an evergreen structure and can allocate up to $3M (in equity or loans) per company. The fund seeks to invest in companies based in the US. The fund is actively seeking new investments and looks to make about 2 allocations in the next 6-9 months.

In the life sciences, the fund is currently seeking to invest in early stage medical devices. The fund is opportunistic in terms of subsectors and indications, but generally does not invest in devices that require a PMA, or which will require over $50 million in total development costs. The fund is particularly interested in dental devices, cosmetics, and mobile technology.

The firm requires a board seat in each portfolio company. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based venture capital firm founded in 2015 is investing from its first fund. The firm invests in early-stage technology companies, and prefers to invest in companies from concept stage through to Series A. The firm expects to invest about $4 million across the life of an investment, with early investments structured as tranches that reflect technological milestones. The firm focuses on companies in the US and Canada, but is open to opportunities globally provided the company is focused on the USA as a primary market.

The firm focuses on building platforms of technology IP. In medical technology, the firm focuses on several specific technology verticals: healthcare robotics (particularly surgical robots), microfluidics (for both diagnostic and biotech R&D purposes), nanotechnology, healthcare 3D printing (including prosthetics, implants and tissue), data science, and the “omic” fields (genomics, proteomics and microbiomics). Technologies that fall between these core areas are also of interest, including biosensors and point of care diagnostics. The firm is open to investing in any disease area, and does not invest in drugs. The firm will only invest in companies developing technologies that have the potential to become a platform that produces a range of products. Repurposed/repositioned technologies are not of interest. Software opportunities will only be considered if the software is patentable.

The firm prefers to invest in very early-stage opportunities, including those that are pre-prototype and pre-patent filing, but may also consider companies that have fully developed their technology. The firm is a highly IP-focused investor and is therefore interested in technological opportunities that can provide both depth and breadth in terms of product potential, particularly those that can develop future applications in industries beyond the life science field.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com